TMS Co., Ltd. (JP:4891) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
TMS Co., Ltd., a clinical-stage biopharmaceutical company, is making strides with its promising lead program, TMS-007, aimed at treating acute ischemic stroke, a field that hasn’t seen a new drug in decades. The company’s CEO, Takuro Wakabayashi, highlighted this potential breakthrough and discussed an emerging pipeline addressing hypertension, kidney injury, and spinal cord injury during an interview on Biotech TV.
For further insights into JP:4891 stock, check out TipRanks’ Stock Analysis page.